Healio

Zoryve cream 0.15% improves atopic dermatitis across diverse skin types

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than a quarter of patients achieved a clear or ...
Monthly Prescribing Reference

Roflumilast Cream 0.05% Under Review for Younger Patients With Atopic Dermatitis

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for roflumilast cream 0.05%, a topical phosphodiesterase-4 inhibitor, for the treatment of ...
Healio

Ruxolitinib cream 1.5% exhibits long-term safety in pediatric atopic dermatitis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. AD affected more than 35% body surface area of study ...
Monthly Prescribing Reference

Zoryve Cream 0.15% for Atopic Dermatitis Now Available

Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...
Seeking Alpha

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...
Yahoo Finance

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA ...
Business Wire

Pooled Results from Incyte’s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced efficacy and safety results from a pooled analysis of two randomized, double-blind, vehicle-controlled Phase 3 studies – ...
The American Journal of Managed Care

Ruxolitinib Cream Successfully Treats Patients With More Severe Atopic Dermatitis

Posters presented at the American Academy of Dermatology Virtual Meeting Experience highlighted that ruxolitinib cream is effective in patients with more severe atopic dermatitis, and even showed ...
Seeking Alpha

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control Rapid and significant improvements in disease clearance with ZORYVE cream ...

I’ve had perioral dermatitis for years — here’s how I finally managed it, plus experts share advice on the common skin condition

Perioral dermatitis is a common skin condition. I share how I finally managed my flare-ups with the help of dermatologists ...
Business Wire

Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic ...

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, ...
Yahoo Finance

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children in the U.S. WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ...